J Golledge1,2, J Moxon1, J Pinchbeck1, G Anderson1, S Rowbotham1,3,4, J Jenkins4, M Bourke1,5, B Bourke5, A Dear6, T Buckenham7, R Jones1, P E Norman8. 1. Queensland Research Centre for Peripheral Vascular Disease, College of Medicine and Dentistry, James Cook University, Townsville, Queensland, Australia. 2. Department of Vascular and Endovascular Surgery, Townsville Hospital, Townsville, Queensland, Australia. 3. School of Medicine, University of Queensland, Brisbane, Queensland, Australia. 4. Royal Brisbane and Women's Hospital, Herston, Queensland, Australia. 5. Gosford Vascular Clinic, Gosford, New South Wales, Australia. 6. Eastern Health Clinical School, Monash University and Department of Medicine, Box Hill Hospital, Melbourne, Victoria, Australia. 7. Christchurch School of Medicine and Health Sciences, Otago University, Christchurch, New Zealand. 8. School of Surgery, University of Western Australia, Fremantle Hospital, Fremantle, Western Australia, Australia.
Abstract
BACKGROUND: It has been suggested that diabetes medications, such as metformin, may have effects that inhibit abdominal aortic aneurysm (AAA) growth. The aim of this study was to examine the association of diabetes treatments with AAA growth in three patient cohorts. METHODS: AAA growth was studied using ultrasound surveillance in cohort 1, repeated CT in cohort 2 and more detailed repeat CT in cohort 3. Growth was estimated by the mean annual increase in maximum AAA diameter. RESULTS: A total of 1697 patients with an AAA were studied, of whom 118, 39 and 16 patients were prescribed metformin for the treatment of diabetes in cohorts 1, 2 and 3 respectively. Prescription of metformin was associated with a reduced likelihood of median or greater AAA growth in all three cohorts (cohort 1: adjusted odds ratio (OR) 0·59, 95 per cent c.i. 0·39 to 0·87, P = 0·008; cohort 2: adjusted OR 0·38, 0·18 to 0·80, P = 0·011; cohort 3: adjusted OR 0·13, 0·03 to 0·61, P = 0·010). No other diabetes treatment was significantly associated with AAA growth in any cohort. CONCLUSION: These findings suggest a potential role for metformin in limiting AAA growth.
BACKGROUND: It has been suggested that diabetes medications, such as metformin, may have effects that inhibit abdominal aortic aneurysm (AAA) growth. The aim of this study was to examine the association of diabetes treatments with AAA growth in three patient cohorts. METHODS: AAA growth was studied using ultrasound surveillance in cohort 1, repeated CT in cohort 2 and more detailed repeat CT in cohort 3. Growth was estimated by the mean annual increase in maximum AAA diameter. RESULTS: A total of 1697 patients with an AAA were studied, of whom 118, 39 and 16 patients were prescribed metformin for the treatment of diabetes in cohorts 1, 2 and 3 respectively. Prescription of metformin was associated with a reduced likelihood of median or greater AAA growth in all three cohorts (cohort 1: adjusted odds ratio (OR) 0·59, 95 per cent c.i. 0·39 to 0·87, P = 0·008; cohort 2: adjusted OR 0·38, 0·18 to 0·80, P = 0·011; cohort 3: adjusted OR 0·13, 0·03 to 0·61, P = 0·010). No other diabetes treatment was significantly associated with AAA growth in any cohort. CONCLUSION: These findings suggest a potential role for metformin in limiting AAA growth.
Authors: Nathan K Itoga; Kara A Rothenberg; Paola Suarez; Thuy-Vy Ho; Matthew W Mell; Baohui Xu; Catherine M Curtin; Ronald L Dalman Journal: J Vasc Surg Date: 2018-09-06 Impact factor: 4.268
Authors: Sydney L Olson; Annalise M Panthofer; William Blackwelder; Michael L Terrin; John A Curci; B Timothy Baxter; Fred A Weaver; Jon S Matsumura Journal: J Vasc Surg Date: 2021-10-14 Impact factor: 4.860
Authors: Xuejuan Ning; Ning Ding; Shoshana H Ballew; Caitlin W Hicks; Josef Coresh; Elizabeth Selvin; James Pankow; Weihong Tang; Kunihiro Matsushita Journal: Atherosclerosis Date: 2020-10-06 Impact factor: 5.162
Authors: Matthew J Nordness; B Timothy Baxter; Jon Matsumura; Michael Terrin; Kevin Zhang; Fei Ye; Nancy R Webb; Ronald L Dalman; John A Curci Journal: J Vasc Surg Date: 2021-10-23 Impact factor: 4.860
Authors: Jenna L Pinchbeck; Joseph V Moxon; Sophie E Rowbotham; Michael Bourke; Sharon Lazzaroni; Susan K Morton; Evan O Matthews; Kerolos Hendy; Rhondda E Jones; Bernie Bourke; Rene Jaeggi; Danella Favot; Frank Quigley; Jason S Jenkins; Christopher M Reid; Ramesh Velu; Jonathan Golledge Journal: J Am Heart Assoc Date: 2018-10-02 Impact factor: 5.501